Assessment of renal dysfunction using the Cockcroft-Gault equation, conducting a study when using vancomycin

Abstract

Background: Vancomycin was first approved by the US Food and Drug Administration (FDA) in 1958. Vancomycin has an active effect on gram-positive microorganisms, such as methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococcus, streptococcus (Enterococcus faecalis), clostridia (Clostridium difÏcile). It is used in the treatment of severe infections such as endocarditis, osteomyelitis, pneumonia, blood and soft tissue infections, other staphylococcal infections and S. epidermis with a β-lactam ring structure that is ineffective or allergic to antibiotics and resistant to many drugs. A study by Marsot and other investigators (2012) determined that the dose of vancomycin in adults is directly dependent on parameters such as creatinine clearance and body weight, as well as the need for dose determination. Aim: A study of renal dysfunction associated with the use of vancomycin Materials and Methods: We used the Cockroft-Gault equation to determine renal dysfunction in 113 inpatients and found grade I in 49.6%, grade II in 15%, grade III in 13.3%, grade IV in 8%, and grade V in 14.2%. Results: There is a statistically significant difference (p=0.003) in renal dysfunction depending on the diagnosis. The average daily dose of vancomycin was 2.5 g, the total daily dose was 8.5 g, the total dose was 20.5 g. The daily dose and total dose of vancomycin were inversely proportional to age (r=-0.256), the daily dose was directly related to excess weight body (r=0.226), and days of vancomycin use are statistically significant (p=0.001) depending on the diagnosis. Conclusion: Vancomycin daily dose is inversely related to age, total dose is inversely related to age, and directly related to BMI. There was no statistically significant difference between the use of vancomycin and the grade of renal dysfunction.